Results 181 to 190 of about 917,021 (263)

The American College of Rheumatology Updated Recommended Methods for Development of Disease Classification and Response Criteria

open access: yesArthritis &Rheumatology, EarlyView.
Disease classification criteria and response criteria are important tools in the conduct of observational studies and clinical trials for rheumatic diseases. This paper updates methodologic guidance for classification and response criteria funded, developed and/or endorsed by the American College of Rheumatology (ACR), incorporating contemporary ...
Sindhu R. Johnson   +4 more
wiley   +1 more source

T Cell Plasticity in Systemic Lupus Erythematosus Revealed by Large‐Scale T Cell Receptor Repertoire and Transcriptome Studies

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to characterize CD4+ T cell plasticity in human systemic lupus erythematosus (SLE) by leveraging T cell receptor (TCR) repertoire features as markers of prior lineage states, integrating TCR and transcriptomic profiling to delineate plasticity patterns and evaluate their association with clinical disease activity. Methods We used TCR
Yasuo Nagafuchi   +11 more
wiley   +1 more source

A Case of Colon Cancer-Induced Hemophagocytic Lymphohistiocytosis with Lymphangitic Carcinomatosis. [PDF]

open access: yesSurg Case Rep
Tachikawa A   +7 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

Editorial note: multiplex real-time PCR diagnostic of relapsing fevers in Africa. [PDF]

open access: yesPLoS Negl Trop Dis
PLOS Neglected Tropical Diseases Editors.
europepmc   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz   +13 more
wiley   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

open access: yesArthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf   +15 more
wiley   +1 more source

Addressing Climate Driven Vector-Borne Disease in West Africa. [PDF]

open access: yesHealth Sci Rep
Edward M   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy